Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Madsen

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Health Science Reports|September 25, 2025
Combining Real-World and Clinical Trial Data Through Privacy-Preserving Record Linkage: Opportunities and Challenges-A Narrative ReviewMichael Batech, Ann Madsen, Nicolle Gatto, et al.
Molecular Genetics and Metabolism|May 1, 2025
Metabolic decompensation events among patients with propionic acidemia across the US: A large electronic medical record data studyVanja Sikirica, Geetanjoli Banerjee, Sue Perera, et al.
Vaccines|February 26, 2025
Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United StatesMawuli Nyaku, Lara S Yoon, Deborah Ricci, et al.
The Journal of Rheumatology|November 16, 2021
Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based StudyJeffrey R Curtis, Xiaofeng Zhou, David T Rubin, et al.
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Plant Physiology|March 11, 2014
Biodesalination: a case study for applications of photosynthetic bacteria in water treatmentJaime M Amezaga, Anna Amtmann, Catherine A Biggs, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world dataPhilip Mease, Christina Charles-Schoeman, Stanley Cohen, et al.
JAMA Network Open|September 30, 2024
Calibrating Observational Health Record Data Against a Randomized TrialDavid Merola, Ulka Campbell, David Lenis, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Health Science Reports|September 25, 2025
Combining Real-World and Clinical Trial Data Through Privacy-Preserving Record Linkage: Opportunities and Challenges-A Narrative ReviewMichael Batech, Ann Madsen, Nicolle Gatto, et al.
Molecular Genetics and Metabolism|May 1, 2025
Metabolic decompensation events among patients with propionic acidemia across the US: A large electronic medical record data studyVanja Sikirica, Geetanjoli Banerjee, Sue Perera, et al.
Vaccines|February 26, 2025
Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United StatesMawuli Nyaku, Lara S Yoon, Deborah Ricci, et al.
The Journal of Rheumatology|November 16, 2021
Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based StudyJeffrey R Curtis, Xiaofeng Zhou, David T Rubin, et al.
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Plant Physiology|March 11, 2014
Biodesalination: a case study for applications of photosynthetic bacteria in water treatmentJaime M Amezaga, Anna Amtmann, Catherine A Biggs, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world dataPhilip Mease, Christina Charles-Schoeman, Stanley Cohen, et al.
JAMA Network Open|September 30, 2024
Calibrating Observational Health Record Data Against a Randomized TrialDavid Merola, Ulka Campbell, David Lenis, et al.
Pageof 4